Aptose Biosciences Inc (NASDAQ:APTO)
| 4.33 Delayed Data As of 3:59pm ET |  -0.14 / -3.13%Today’s Change | 3.92 Today|||52-Week Range 9.25 | -1.14% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $391.0M |
Company Description
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
Contact Information
Aptose Biosciences, Inc. 251 Consumers Road Toronto Ontario M2J 4R3 |
Employees
Shareholders
| Mutual fund holders | -- |
| Individual stakeholders | -- |
| Other institutional | -- |
Top Executives
| William G. Rice | Chairman, President & Chief Executive Officer |
| Gregory K. Chow | Chief Financial Officer & Senior Vice President |
| Rafael Bejar | Chief Medical Officer & Senior Vice President |
| Victor Montalvo-Lugo | Vice President-Clinical Operations |
| Ernest Kitt | Vice President-Development & Technical Operations |
